IRCT20140818018842N26 IRCT 2022-11-28 Tehran University of Medical Sciences Cell therapy for Refractory Lymphoid Malignancies Rituximab and Allogeneic Natural Killer Cells for Refractory Lymphoid Malignancies 2022-12-11 anticipated 10 Complete https://irct.ir/trial/66646 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1 Condition 1: Hodgkin lymphoma. Condition 2: Follicular lymphoma. Condition 3: Non-follicular lymphoma. Intervention group: All patients are included in the only intervention arm of the study. Patients in the intervention arm will receive a dose of 10 million/kg expanded NK cells on the day after the conditioning regimen. The injection of cells will be done within 30 minutes under full supervision and in an isolated room. The process of isolation and preparation of NK cells will be done in a clean room with clinical grade and suitable conditions for producing NK cells. From 21 days before the infusion, 20 to 30 cc of peripheral blood was taken from the third-party donor and after the isolation of mononuclear cells, CD56+/CD3- reproduced. A viability test is done using trypan blue and phenotyping is used to check the absolute number and purity of cells.. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information